Home / Library / Tirzepatide weight loss by dose: what each rung delivers

Results · the dose-response, read correctly

Tirzepatide weight loss by dose: what each rung delivers

Published 2026-08-14 · 6 min read · By the research team · pending clinician sign-off

The ladder, rung by rung

2.5 mg (weeks 1–4): the on-ramp — chosen to build GI tolerance, deliberately sub-therapeutic, with appetite effects real but scale expectations properly small; judging the drug here is judging a warm-up lap. 5 mg: the first true treatment dose and the most underrated number in the program — 15% average loss is roughly triple what older weight-loss drugs managed, and for many people 5 mg is a destination, not a waypoint; it's also where flat-rate pricing starts earning its keep, since dose-priced programs begin their climbs here. 7.5 mg: the untrialed-as-maintenance middle step — SURMOUNT-1 didn't run a 7.5 mg arm, but clinical practice uses it constantly as a landing spot between the studied rungs, and response there interpolates sensibly. 10 mg: the efficiency peak — 19.5% average captures nearly all of the drug's demonstrated effect, which is why many prescribers treat 10 mg as the default ceiling absent a reason to push. 12.5–15 mg: the top tiers, adding roughly a point and a half of average loss over 10 mg while carrying the highest GI-effect and (on dose-priced and brand programs) cost burden — genuinely valuable for partial responders, unnecessary for people already succeeding lower.

How to actually use a dose-response curve

The averages describe populations; your decision uses them differently. The operating principle clinicians apply: escalate for inadequate response, not by calendar loyalty — the four-week intervals are minimums, and a patient losing steadily at 5 mg has no obligation to climb (every rung skipped is side-effect exposure and, on many programs, money saved). The reverse also holds: a stall at 5 mg after honest weeks, with the diagnostic checklist cleared, is exactly what the 10 mg data exists for — the 5→10 jump is where the curve pays best. Individual variance deserves its honest paragraph: distributions around every average are wide — some 5 mg patients beat the 15 mg average, some 15 mg patients trail the 5 mg one — and dose escalation shifts your odds rather than guaranteeing your outcome, which is why predefined checkpoints (what result, by when, triggers what decision) beat vibes at every rung.

The money layer: what each rung costs where

Dose intersects price differently across the market, and the intersection is half of real-world dosing decisions. Flat-rate programs (NexLife's displayed $169/139 structure, Embody's reported $119–129, Remedy's $399) charge the same at 5 and 15 mg — making the medical question the only question, the structural argument for them our pricing method scores. Dose-priced programs climb with you — the aggregator-reported pattern of $30–80/month added at top tiers — meaning the 10-vs-15 decision carries a price tag exactly where its medical payoff thins. LillyDirect vials price the ladder explicitly: $299 (2.5) / $399 (5) / $449 (7.5–15 in-window), so brand patients pay the biggest increment at the first real step and nothing more to climb thereafter. The synthesis: on flat programs, find your minimum effective dose for tolerability; on dose-priced ones, the same search is also a budget strategy; and on any of them, the phrase worth writing into your plan is the one this page keeps circling — lowest effective dose, discovered deliberately, revisited at maintenance per the step-down playbook.

Dose equivalence across products: the switching table in prose

The ladder's milligrams stay constant across every legitimate tirzepatide product — 5 mg is 5 mg in a Zepbound pen, a LillyDirect vial, or a compounded vial — but the delivery of those milligrams changes, and that's where switchers get hurt. Brand pens dispense fixed doses mechanically: your prescription's rung is the pen you receive, no math involved. Vials — brand or compounded — dispense by volume, so the same 5 mg might be 0.5 mL from a 10 mg/mL vial or 0.25 mL from a 20 mg/mL one (NexLife's published microdose concentration, for instance, is 20 mg/mL per its product imaging), and every product change is a concentration change until proven otherwise. The three switching scenarios and their rules: pen→vial, own the units formula before the first draw; vial→vial across providers, recalculate even if the dose is "the same" — this is the market's most common injury mechanism, per the dosage chart; and any switch involving in-between compounded doses (6 mg maintenance, say) onto the brand ladder means your prescriber rounds you to a rung — a conversation about which direction, not a pharmacy improvisation. One equivalence that does not exist: tirzepatide↔semaglutide has no conversion table — different molecules restart at the destination drug's initiation dose, full stop, per the switching protocol.

The escalation worksheet: five questions before every step up

Turn the escalate-or-hold decision into a form you fill monthly rather than a feeling you have weekly. One: what did the last four weeks' seven-day averages actually do? Steady movement (any consistent downward trend) is a working dose — the default answer is hold. Two: is the current dose livable? Side effects still disrupting eating, sleep, or work at week four argue for a longer hold or a slower plan, not a bigger dose on a struggling gut. Three: did anything else change? Travel, illness, a new medication, a rough month — noise weeks don't justify dose decisions in either direction. Four: what's the price of the next rung? Zero on flat-rate programs, real money on dose-priced ones and on the LillyDirect $399→$449 step — worth knowing before the medical marginal benefit gets weighed. Five: what result, by when, will tell us the step worked? Write the checkpoint down — "reassess at six weeks; success is the average moving again" — because pre-committed criteria are the only known cure for the escalate-forever drift that lands people at 15 mg by default. Bring the five answers to the prescriber conversation and you've done their favorite kind of visit; notice a program that escalates you on a calendar without ever asking question one, and you've learned something about the program.

What the trials say about tolerability by rung

The dose-response has a side-effect curve too, and it shapes the strategy. SURMOUNT-1's discontinuation-for-adverse-events rates climbed modestly with dose — single digits across arms, but higher at 15 mg than 5 — and the GI-event frequencies (nausea, diarrhea, constipation) followed the same gentle slope, concentrated in titration windows at every rung rather than at steady state. Two strategic readings: first, the tolerability price of the top tiers is real but not dramatic for those who get there gradually — the misery stories mostly come from pace, not altitude, which is why every interval being a minimum matters more than which rung you end on; second, the combination of modest marginal efficacy (the ~1.4-point 10→15 gain) and modestly higher side-effect load is exactly why "highest tolerated dose" has been quietly replaced in careful practice by "lowest effective dose" — the same result-per-discomfort logic, run in the patient's favor. The practical synthesis for the anxious escalator: the data says most of the drug's benefit and most of its comfort live in the 5–10 mg band, the top tiers exist for the minority who need them, and a titration that reaches "enough" and stops is not leaving results on the table — it's the trial curves, applied with judgment.

The one-paragraph decision rule

If the ladder's numbers blur, keep only this: start where everyone starts, climb only when four honest weeks of averages say the current rung has stopped paying, stop climbing the moment steady progress and livable side effects coexist, and write down what would make you step in either direction before feelings volunteer to decide. The trials prove the top rungs exist for the people who need them; the same trials prove most of the drug lives lower on the ladder — and the patients who do best treat dose as a dial they own jointly with a prescriber, not an escalator they ride to the top because it was moving.

Reading your own response against the curve

A final calibration tool: place yourself on the distribution honestly before any escalation talk. Compute your percent lost from baseline at your current rung's twelve-week mark and compare it to that rung's trajectory — a 5 mg patient at 6% by week twelve is tracking the 15%-at-72-weeks arc beautifully and needs nothing; the same patient at 1.5% with clean diagnostics is genuinely below curve and is exactly who the next rung was trialed for. Two distortions to subtract first: starting BMI shifts percentage math (higher baselines often post larger early percentages), and the water-weight opening week flatters everyone's month one — which is why the comparison starts at week twelve, not week four. Run the placement once per rung, write the sentence it produces ("tracking / below / above, because…"), and every future dose conversation begins with evidence instead of impressions — the whole dose-response literature, finally pointed at its only real subject: you.

FAQ

What is the average weight loss on 5 mg of tirzepatide?

15.0% of body weight at 72 weeks in SURMOUNT-1 — a fully therapeutic result many patients maintain without ever climbing higher.

Is 15 mg of tirzepatide worth it over 10 mg?

On averages, 15 mg adds ~1.4 points over 10 mg's 19.5% — the smallest jump on the ladder, with the highest side-effect load. It earns its place for partial responders at 10 mg, not as a default destination.

Do you lose weight on 2.5 mg of tirzepatide?

Some, and appetite effects are real — but 2.5 mg is the initiation dose, studied as a 4-week on-ramp rather than a maintenance arm. Treat it as tolerance-building.

Related: Results timeline by phase · Microdosing & minimum-effective dosing · Units & concentration math · Plateau diagnostics

Educational content, not medical advice — dosing, switching, and side-effect decisions belong with your prescriber. Sources and trial citations: the source library. Corrections within 48 hours: policy.